Physician profile
Thomas John Davidson
NPI 1295171858
$2,065.28
in general payments reported to CMS, 2019-2025
15 companies · $200 in 2025
The $200 reported for 2025 was less than what a typical Primary Podiatric Medicine provider received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $129 · 2021: $534 · 2022: $447 · 2023: $601 · 2024: $154 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $954.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Next Science LLC | $302.16 | 2023-2024 | Surgx, Blastx, Xperience |
| Organogenesis INC. | $228.19 | 2020-2021 | |
| Kerecis Limited | $175.29 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Orthofix Medical, INC. | $169.47 | 2021 | |
| Bioventus LLC | $166.36 | 2022-2025 | Exogen Ultrasound Bone Healing System |
| Averitas Pharma INC. | $163.76 | 2023 | Qutenza |
| Acera Surgical, INC. | $149.03 | 2023 | Restrata Wound Matrix |
| Smith+Nephew, INC. | $147.38 | 2022 | |
| Innovation Technologies INC | $124.99 | 2023 | Irrisept |
| Advanced Oxygen Therapy INC. | $124.99 | 2022 | |
| Misonix INC | $124.00 | 2021 | |
| Melinta Therapeutics, LLC | $115.88 | 2021 | |
| Paratek Pharmaceuticals, INC. | $32.80 | 2022 | |
| Kci USA, INC. | $26.00 | 2020 | |
| Musculoskeletal Transplant Foundation INC. | $14.98 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.